cancerBiology180x110

BXQ-350 – Pre-clinical Cancer Drug with Novel Mechanism of Action

Bexion Pharmaceuticals received Orphan Drug Designation for its novel drug, BXQ-350 for the treatment of patients with glioblastoma multiforme. The drug has shown activity in over 60 different cancer cell lines, and is toxic to cancer cells, only.The nanovesicals bypass the blood brain barrier. Continue reading

cancerBiology180x110

Innate Pharma – Two NK Cell Checkpoint Inhibitors in Development

Natural Killer cells and macrophages are essential in the innate immune response to bacterial pathogens. They also provide the essential link to the adaptive immune response by presenting antigens to dendritic cells and by directly stimulating CD8+ cytotoxic T-cells.  Continue reading

cancerBiology180x110

Iontophoresis: Electric Fields as a New Innovative Way to Deliver Chemotherapy. Guest Contributor – Mariah J. Scott

Researchers at the University of North Carolina have been developing a chemotherapy drug treatment utilizing iontophoresis specifically for prostate and breast cancer. Continue reading

cancerBiology180x110

Bavituximab – Novel Checkpoint Inhibitor in Phase 3

Bavituximab is a monoclonal antibody that binds to phosphatidyl serine (PS), a molecule this is expressed in the inner side of the cell membrane. The drug is being developed by Peregrine Pharmaceuticals for the treatment of non-small cell lung cancer and is in a late stage trial called SUNRISE –  A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Previously Treated Stage IIIb/IV Non-Squamous Non Small-Cell Lung Cancer. Continue reading

cancerBiology180x110

Experimental Front-Line Treatment for Head & Neck Cancer in Phase III

Multikine is a new product being developed by CEL-SCi for front-line use in patients with head and neck cancer. I observed a presentation at the 2015 Biotech Showcase on January 12, 2015. A late stage clinical trial is currently enrolling – Phase III Study of LI [Multikine®] Plus SOC (Surgery + Radiotherapy or Surgery + Concurrent Radiochemotherapy) in Subjects With Advanced Primary Squamous Cell Carcinoma of the Oral Cavity/Soft Palate vs. SOC Only. Continue reading

cancerBiology180x110

Rexahn – 3 Novel Cancer Products in Development

I attended the Rexahn presentation at the Biotech Showcase on January 12-14, 2015. The company has 3 novel anti-cancer products in the clinic. Continue reading

cancerBiology180x110

Adenosine Receptor Agonist for Liver Cancer

Can-Fite BioPharma announced that it has dosed the first patient in a Phase II trial for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. The study will enroll 78 patients with refractory advanced hepatocellular carcinoma  with Child-Pugh Class B cirrhosis. Patients will receive 25 mg of CF102 orally twice a day; the endpoint will be overall survival between those receiving CF102 versus placebo. Continue reading

cancerBiology180x110

Mystery of Myeloid-Derived Suppressor Cells in Cancer SOLVED

Researchers at St. Jude Children’s hospital have identified the population of white blood cells that tumors use to propagate their growth AND to suppress the immune system.   Continue reading

3LINVBW

Merck Acquires OncoEthix for Novel MYC Blocker

Last week, Merck acquired OncoEthix at a price of $375 MM for OTX015, a synthetic small molecule which targets the BET bromodomain proteins 2, 3, and 4 (BRD2/3/4). Continue reading